SILO
Silo Pharma, Inc.
Biotechnology
Market Cap$2M
5Y Perf.+20.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SILO vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-57.3%
SILO vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SILO | MNMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2M | $2.04B |
| Revenue (TTM) | $72K | $0.00 |
| Net Income (TTM) | $-5M | $-238M |
| Gross Margin | -8.1% | — |
| Operating Margin | -74.5% | — |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $4M | $258M |
SILO vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SILO
MNMD
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| Silo Pharma, Inc. (SILO) | 100 | 120.3 | +20.3% |
| Mind Medicine (Mind… (MNMD) | 100 | 42.7 | -57.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SILO vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNMD leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Silo Pharma, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
SILO
Silo Pharma, Inc.
The Growth Play
SILO is the clearest fit if your priority is growth exposure.
- Rev growth 0.0%, EPS growth 0.8%, 3Y rev CAGR 0.4%
- 0.0% revenue growth vs MNMD's -96.9%
Best for: growth exposure
MNMD
Mind Medicine (MindMed) Inc.
The Income Pick
MNMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.68
- 5.1% 10Y total return vs SILO's 20.0%
- Lower volatility, beta 1.68, current ratio 6.29x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SILO | 0.0% revenue growth vs MNMD's -96.9% |
| Quality / Margins | MNMD | 1.2% margin vs SILO's -70.4% |
| Stability / Safety | MNMD | Beta 1.68 vs SILO's 2.21 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs SILO's -48.1% |
| Efficiency (ROA) | MNMD | -70.7% ROA vs SILO's -79.5%, ROIC -389.5% vs -186.7% |
SILO vs MNMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGSILO
SILOSilo Pharma, Inc.
1leads
MNMDMind Medicine (MindMe…
3leads
6 Total Categories
CATEGORYLEADERvs SILOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SILO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNMD5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
MNMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SILO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SILO and MNMD operate at a comparable scale, with $72,102 and $0 in trailing revenue.
| Metric | SILOSilo Pharma, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| RevenueTrailing 12 months | $72,102 | $0 |
| EBITDAEarnings before interest/tax | -$5M | -$191M |
| Net IncomeAfter-tax profit | -$5M | -$238M |
| Free Cash FlowCash after capex | -$5M | -$174M |
| Gross MarginGross profit ÷ Revenue | -8.1% | — |
| Operating MarginEBIT ÷ Revenue | -74.5% | — |
| Net MarginNet income ÷ Revenue | -70.4% | — |
| FCF MarginFCF ÷ Revenue | -66.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | 0.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +45.5% | -163.0% |
SILO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SILO and MNMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SILOSilo Pharma, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| Market CapShares × price | $2M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.35x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 26.12x | — |
| Price / BookPrice ÷ Book value/share | 0.31x | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SILO and MNMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNMD leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
SILO delivers a -101.4% return on equity — every $100 of shareholder capital generates $-101 in annual profit, vs $-102 for MNMD. On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs SILO's 2/9, reflecting mixed financial health.
| Metric | SILOSilo Pharma, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| ROE (TTM)Return on equity | -101.4% | -102.5% |
| ROA (TTM)Return on assets | -79.5% | -70.7% |
| ROICReturn on invested capital | -186.7% | -3.9% |
| ROCEReturn on capital employed | -74.0% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$4M | -$258M |
| Cash & Equiv.Liquid assets | $4M | $258M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -1053.72x | -21.81x |
MNMD leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SILO five years ago would be worth $16,471 today (with dividends reinvested), compared to $4,205 for MNMD. Over the past 12 months, MNMD leads with a +214.0% total return vs SILO's -48.1%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs SILO's -42.6% — a key indicator of consistent wealth creation.
| Metric | SILOSilo Pharma, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| YTD ReturnYear-to-date | +25.0% | +51.7% |
| 1-Year ReturnPast 12 months | -48.1% | +214.0% |
| 3-Year ReturnCumulative with dividends | -81.1% | +510.3% |
| 5-Year ReturnCumulative with dividends | +64.7% | -57.9% |
| 10-Year ReturnCumulative with dividends | +20.0% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -42.6% | +82.7% |
MNMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
MNMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNMD is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than SILO's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs SILO's 37.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SILOSilo Pharma, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.21x | 1.68x |
| 52-Week HighHighest price in past year | $1.13 | $21.09 |
| 52-Week LowLowest price in past year | $0.22 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +37.2% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 47.0 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 4.6M | 792K |
MNMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SILOSilo Pharma, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $20.00 |
| # AnalystsCovering analysts | — | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +9.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). SILO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 3 of 6 categories
Loading custom metrics...
SILO vs MNMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SILO or MNMD a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SILO or MNMD?
Over the past 5 years, Silo Pharma, Inc.
(SILO) delivered a total return of +64. 7%, compared to -57. 9% for Mind Medicine (MindMed) Inc. (MNMD). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus SILO's +20. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SILO or MNMD?
By beta (market sensitivity over 5 years), Mind Medicine (MindMed) Inc.
(MNMD) is the lower-risk stock at 1. 68β versus Silo Pharma, Inc. 's 2. 21β — meaning SILO is approximately 31% more volatile than MNMD relative to the S&P 500.
04Which is growing faster — SILO or MNMD?
On earnings-per-share growth, the picture is similar: Silo Pharma, Inc.
grew EPS 0. 8% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SILO or MNMD?
Mind Medicine (MindMed) Inc.
(MNMD) is the more profitable company, earning 0. 0% net margin versus -60. 9% for Silo Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -65. 3% for SILO. At the gross margin level — before operating expenses — SILO leads at 91. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SILO or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SILO or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Silo Pharma, Inc. (SILO) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, SILO: +20. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SILO and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.